MSL
RGNX icon

Mackay Shields LLC’s Regenxbio RGNX Stock Holding History

Mackay Shields LLC’s Portfolio RGNX Stock Details RGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-42,057
Closed -$1.43M – 1192
2021
Q1 		$1.43M Sell
42,057
-26,812
-39% -$1.14M 0.01% 895
2020
Q4 		$3.12M Buy
68,869
+3,700
+6% +$129K 0.02% 651
2020
Q3 		$1.79M Buy
65,169
+19,200
+42% +$626K 0.01% 835
2020
Q2 		$1.69M Buy
45,969
+13,600
+42% +$507K 0.01% 832
2020
Q1 		$1.05M Buy
32,369
+3,500
+12% +$146K 0.01% 931
2019
Q4 		$1.18M Sell
28,869
-6,500
-18% -$257K 0.01% 1034
2019
Q3 		$1.26M Buy
35,369
+6,700
+23% +$271K 0.01% 1059
2019
Q2 		$1.47M Buy
28,669
+17,712
+162% +$884K 0.01% 1017
2019
Q1 		$628K Buy
10,957
+1,100
+11% +$54.5K ﹤0.01% 1126
2018
Q4 		$414K Sell
9,857
-1,043
-10% -$61.2K ﹤0.01% 1197
2018
Q3 		$823K Sell
10,900
-600
-5% -$43.2K 0.01% 923
2018
Q2 		$825K Buy
+11,500
New +$549K 0.01% 1006

Other funds holding RGNX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Mackay Shields LLC's RGNX Position: Q2 2021 in Review

Mackay Shields LLC sold out of Regenxbio (RGNX) in Q2 2021, closing a stake of 42,057 shares — an estimated $1.43M sold.

Mackay Shields LLC first reported a position in RGNX in Q2 2018 and held it in 12 quarters. The position peaked at $3.12M in Q4 2020. 172 funds tracked by Wall St. Rank hold RGNX as of Q2 2021.

  • Mackay Shields LLC reported no remaining Regenxbio position as of Q2 2021 after selling out during the quarter.
  • Mackay Shields LLC sold 42,057 Regenxbio shares in Q2 2021, an estimated $1.43M.
  • Mackay Shields LLC first reported a position in Regenxbio in Q2 2018 and held it in 12 quarters.
  • Mackay Shields LLC's Regenxbio position peaked at $3.12M in Q4 2020.
  • 172 funds tracked by Wall St. Rank held Regenxbio as of Q2 2021.

Based on Mackay Shields LLC's 13F filing for Q2 2021, filed 13 Aug 2021.